Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Debamestrocel - BrainStorm Cell Therapeutics

Next Previous
Drug Profile

Debamestrocel - BrainStorm Cell Therapeutics

Alternative Names: Autologous bone marrow derived mesenchymal stem cell therapy - BrainStorm Cell therapeutics; Autologous MSC-NTF; Bone-marrow-derived-mesenchymal-stem-cells-BrainStorm; GDNF therapy; GDNf-stem-cell-therapy-BrainStorm-Cell-Therapeutics; Glial-cell-line-derived-neurotrophic-factor-producing-adult-bone-marrow-derived-stem-cell-therapy-BrainStorm Cell Therapeutics; Glial-cell-line-derived-neurotrophic-factor-stem-cell-therapy-BrainStorm; MSC-NTF; MSC-NTF cell; MSC-NTF-BrainStorm-Cell-Therapeutics; Neurotrophic factor-producing mesenchymal stem cell therapy - BrainStorm Cell Therapeutics; Neurotrophic factor-secreting stem cell therapy; Neurotrophic-factor-producing-adult-stem-cell-therapy-BrainStorm; NurOwn; NurOwn-GDNF-therapy; NurOwn™ program one

Latest Information Update: 12 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tel Aviv University
  • Developer Brainstorm Cell Therapeutics; Hadassah Medical Organization; Tel Aviv University
  • Class Exosome therapies; Mesenchymal stem cell therapies; Stem cell therapies
  • Mechanism of Action Dopaminergic cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Amyotrophic lateral sclerosis; Multiple sclerosis
  • Preclinical Acute lung injury; Huntington's disease; Parkinson's disease; Peripheral nerve injuries; Pervasive child development disorders
  • No development reported Sciatica; Spinal cord injuries

Most Recent Events

  • 09 Apr 2024 BrainStorm Cell Therapeutics receives agreement under special protocol assessment from the FDA for neurotrophic factor producing mesenchymal stem cell therapy in Amyotrophic lateral sclerosis
  • 09 Apr 2024 Brainstorm Cell Therapeutics plans a phase IIIb trial for Amyotrophic lateral sclerosis in 2024
  • 23 Feb 2024 BrainStorm Cell Therapeutics expects response on SPA from US FDA for Amyotrophic lateral sclerosis within 45 days from the date of submission
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top